Physician profile
Sharon J Mitchell
NPI 1396747234
$1,633.61
in general payments reported to CMS, 2019-2025
21 companies · $18.96 in 2025
The $18.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $416 · 2021: $50.59 · 2022: $38.76 · 2023: $127 · 2024: $127 · 2025: $18.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $372.12 | 2019-2020 | |
| Novo Nordisk INC | $270.66 | 2019-2024 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $141.77 | 2019-2020 | |
| Amgen INC. | $133.85 | 2019-2022 | |
| Radius Health, INC. | $129.45 | 2019-2023 | Tymlos |
| Ethicon US, LLC | $124.17 | 2019 | |
| Lilly USA, LLC | $103.39 | 2019-2024 | Mounjaro |
| Pfizer INC. | $73.35 | 2019-2022 | |
| Abbvie INC. | $50.59 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.20 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $30.65 | 2019-2023 | Veozah |
| Lundbeck LLC | $29.16 | 2023 | Rexulti |
| Exact Sciences Corporation | $23.90 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $17.69 | 2024 | Sunosi |
| Janssen Pharmaceuticals, INC | $17.44 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $17.18 | 2023 | Lybalvi |
| Glaxosmithkline, LLC. | $14.04 | 2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.75 | 2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $13.32 | 2019 | |
| Mylan Specialty L.P. | $13.17 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.